Updated
Korsana BiosciencesKRSA · Healthcare
$31.05+2.04%
Market cap$132M
IndustryBiotechnology
Korsana Biosciences (KRSA) Revenue breakdown
By product, Revenue from license agreement is the largest at 48% of fiscal 2025 revenue; Revenue from option agreement grew fastest, 10% a year over 1 years.
Revenue by product
Fiscal years, as Korsana Biosciences reports them in its 10-K filings; fiscal 2025 total $2M.
| Products | 2024 | 2025 | Share |
|---|---|---|---|
| Revenue from license agreement | $2M | $1M | 48% |
| Revenue from purchase agreement | — | $800,000 | 39% |
| Revenue from option agreement | $250,000 | $274,000 | 13% |
Questions about Korsana Biosciences
Where does Korsana Biosciences make its money?
In fiscal 2025, by product: Revenue from license agreement $1M, Revenue from purchase agreement $800,000, Revenue from option agreement $274,000.
From Korsana Biosciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.